Posts by: Patricia Inacio PhD

News

The results of a new T cell therapy study entitled “T Cells Engineered with a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Have Long-Term Persistence and Induce Durable Remissions in ... Read more

October 20, 2014October 20, 2014

Enumeral’s Immuno-Oncology Profiling Awarded Phase II SBIR Contract

News

Enumeral, a company dedicated to the development of novel antibody immunotherapies, was awarded a Phase II Small Business Innovation Research (SBIR) contract from the National Cancer Institute (NCI). The project ... Read more

October 17, 2014September 9, 2015

New Phase I-II Clinical Trial To Evaluate Ibrutinib And Nivolumab Combination in Lymphoma Patients

News

A new Phase I-II clinical trial for non-Hodgkin lymphoma (NHL) patients will evaluate the combination therapy of PD-1 immune checkpoint inhibitor nivolumab (Opdivo) and the oral BTK inhibitor ibrutinib (Imbruvica). The announcement ... Read more

September 22, 2014September 22, 2014

National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics

News

KIYATEC – a company developing 3D cell-based models for drug response profiling – has been awarded a Small Business Innovation Research (SBIR) Phase II Contract. The 1.975 million dollar grant ... Read more

September 4, 2014September 4, 2014

Motolimod (VTX-2337) Fast Tracked By FDA For the Treatment of Women with Ovarian Cancer

News

Women diagnosed with ovarian epithelial cancer often experience persistence or recurrence of the disease following treatment with platinum-based chemotherapy. This phenomenon occurs in women within 6-12 months of completion with ... Read more